Billable / Specific Code
ICD-10-CM D09.3 is the diagnosis code for Carcinoma in situ of thyroid and other endocrine glands. This code falls under the section "In situ neoplasms" within Chapter 2 — Neoplasms (C00-D49). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
The following conditions should never be coded at the same time as D09.3. They are mutually exclusive:
Understanding where D09.3 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, D09.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
D09.3 is the ICD-10-CM diagnosis code for "Carcinoma in situ of thyroid and other endocrine glands". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of D09.3 is D09 ("Carcinoma in situ of other and unspecified sites"). D09.3 provides a more specific classification within this category.
D09.3 is located in Section D00-D09 — "In situ neoplasms" within Chapter 2 of the ICD-10-CM Tabular List.
Use D09.3 when the patients documented diagnosis matches "Carcinoma in situ of thyroid and other endocrine glands" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Carcinoma in situ of thyroid and other endocrine glands is D09.3.
Yes, D09.3 can be used as a primary diagnosis code since it is billable and specific.
D09.3 is in Chapter 2 of the ICD-10-CM Tabular List.
Type 1 Excludes for D09.3 include: carcinoma in situ of endocrine pancreas (D01.7); carcinoma in situ of ovary (D07.39); carcinoma in situ of testis (D07.69).
Yes, D09.3 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.